shutterstock_1732246315_repelsteeltje
Repelsteeltje / Shutterstock.com
5 February 2021BiotechAlex Baldwin

Pfizer to collaborate with Imcyse on new immunotherapy programme

Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis (RA) using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
17 November 2026   A US judge tosses an antitrust lawsuit accusing Alexion of using sham patent litigation to delay competition to Soliris, finding that its favourable settlement with a rival undermined the claims.
Biotech
16 November 2026   The Swiss pharma giant will work with a Taiwan-based biotech’s ADC platform technologies to develop next-generation cancer therapies in a deal worth potentially more than $2bn, including $30m upfront.
Biotech
13 November 2026   Curiox claims confidential information shared during talks about a potential business partnership was used to develop a competing cell preparation system within months, despite the South Korean company spending years developing its own technology.